Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mylan’s EpiPen Recall: Adding Insult To An Injured Product

Executive Summary

Pricing controversy around the product got the CEO hauled before Congress; now what began as an overseas recall of one lot made by a Pfizer subsidiary threatens to besmirch Mylan’s once golden supply chain quality record.


Related Content

Mylan’s Generic Advair Delay Gives Leverage To Rivals
Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
EpiPen Rival Heads Back To Market After kaléo Retools With ‘100% Automated’ Production
Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review
Mylan Hit With GMP Warning Letter Despite Quality Improvement Efforts
GDUFA Implementation Will Be Overseen By Mylan’s Representative in the House
Mylan Gets First-Ever GMP Warning Letter
Establishment Fees Protect American Manufacturing, Mylan Argues In User Fee Proposal


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst